0%
Print report
Variant interpretation report

FLT3 c.1664T>A, p.Ile555Asn

NM_004119.2:c.1664T>A NP_004110.2:p.(Ile555Asn) Missense · exon 13 View identifiers
Classification
Uncertain significance

Variant description:

The FLT3 NM_004119.2:c.1664T>A (NP_004110.2:p.(Ile555Asn)) missense variant has previously been reported in somatic cancers (COSMIC; COSV106090853, n = 1 time). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About FLT3

FLT3 encodes a receptor tyrosine kinase that helps regulate hematopoiesis, the formation and development of blood cells, through signaling pathways that control blood cell growth, survival, and differentiation. Mutations that keep the receptor permanently activated contribute to acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In AML, FLT3 is one of the most frequently altered genes, with internal tandem duplications seen in about a quarter of cases and kinase-domain point mutations in about 7%, and drugs targeting FLT3 are currently in clinical development.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Local FLT3 ITD / activating length-mutation framework. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 0
Pathogenic criteria applied · 1
PM2Moderate
PM2 · moderate

Met at Moderate: gnomAD v4.1 total AF is 1.23906e-06 with 0 homozygotes, below the <=0.0001 PM2 cutoff.

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Uncertain significance

VUS: PM2 (moderate) is the only applied criterion and does not satisfy a pathogenic or benign combination rule under the local FLT3 framework.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
2 / 1,614,128 alleles

gnomAD v4.1: 2 / 1,614,128 alleles. Recorded AF 1.23906e-06. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.97687e-06; MAF= 0.00040%, 1/251454 alleles, homozygotes = 0) and has highest observed frequency in the South Asian population (AF= 3.26627e-05; MAF= 0.00327%, 1/30616 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

No screenshot for this evidence
REVEL score
0.561 recorded score

Recorded REVEL score: 0.561. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied
No screenshot for this evidence
ClinVar submissions
Not recorded

A ClinVar laboratory submission summary was not recorded.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. FLT3, a receptor tyrosine kinase, is recurrently altered in acute myeloid leukemia and other hematologic malignancies.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
1 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV106090853, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Local FLT3 ITD / activating length-mutation framework, with the data and sources behind each one.

28 criteria with recorded statuses: 1 met · 10 not met · 12 not assessed · 5 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

All four requested segregation/de novo criteria are not assessed because the available evidence contains no proband-level pedigree, parental testing, affected-relative genotypes, or informative meioses for NM_004119.2:c.1664T>A (p.Ile555Asn).

Neither PS3 nor BS3 can be assessed from the available variant-specific functional evidence under generic ACMG/AMP 2015; class-level FLT3 ITD literature is not sufficient for this missense substitution, and no exact-variant VCEP table entry was found.

PS4 was evaluated against the ACMG/AMP 2015 case-control definition; the only extracted full-text paper was verified as not mentioning the exact variant and supplied no case-control counts.

PP4 and BP5 are not assessed because the case materials lack the phenotype/family-history and alternate-molecular-basis facts required by their definitions.

PP5 and BP6 are not met because the exact variant is absent from ClinVar and there is no qualifying expert-panel classification.

Met · 1

PM2 ModerateACMG_2015Met at Moderate: gnomAD v4.1 total AF is 1.23906e-06 with 0 homozygotes, below the <=0.0001 PM2 cutoff. Details ▾Hide ▴
Reasoning

PM2 is met at the required ACMG/AMP 2015 Moderate strength. The variant is present only at extremely low frequency in population controls: gnomAD v4.1 total AF=1.23906e-06 (2/1,614,128 alleles; 0 homozygotes), with grpmax FAF=3.65e-06, and gnomAD v2.1 total AF=3.97687e-06 (1/251,454 alleles; 0 homozygotes). These values are below the supplied <=0.0001 cutoff for extremely low frequency, and no governing VCEP rule requires a non-cancer or exome-only subset.

Rule
Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v4.1 reports AF=1.23906e-06, 2/1,614,128 alleles, 0 homozygotes, and grpmax FAF=3.65e-06.
  • gnomAD v2.1 reports AF=3.97687e-06, 1/251,454 alleles, and 0 homozygotes.
  • Both observed frequencies are below the supplied generic PM2 extremely-low-frequency cutoff of <=0.0001 (0.01%); no governing VCEP specifies use of a non-cancer or exome-only subset for this case.
Sources

Not met · 10 · evaluated, threshold not reached

PS1 ACMG_2015Not met: no previously established pathogenic variant producing FLT3 p.Ile555Asn was identified for this missense substitution. Details ▾Hide ▴
Reasoning

PS1 is not met. The normalized variant is NP_004110.2:p.(Ile555Asn), also p.(I555N). The case evidence contains no previously established pathogenic variant producing the same amino-acid change, and no exact-variant or same-amino-acid entry was found in the governing FLT3 files. The searched files flt3_itd_hotspot_and_function.md.txt and flt3_oncokb_guidance.md.txt contain no notation for c.1664T>A, p.Ile555Asn, or p.I555N. The local FLT3 notes are restricted to ITD/activating length-mutation events and do not establish PS1 evidence for this missense substitution.

Rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change. ... Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level.
Evidence considered
  • Normalization in the case evidence identifies NM_004119.2:c.1664T>A as NP_004110.2:p.(Ile555Asn), p.(I555N).
  • The searched FLT3 governing files contain no entry for c.1664T>A, p.Ile555Asn, or p.I555N; their stated scope is FLT3 ITD/activating length-mutation events rather than this missense substitution.
Still missing
  • No c.1664T>A, p.Ile555Asn, or p.I555N entry was found in flt3_itd_hotspot_and_function.md.txt.
  • No c.1664T>A, p.Ile555Asn, or p.I555N entry was found in flt3_oncokb_guidance.md.txt.
PS4 ACMG_2015Not met: no variant-specific affected-versus-control carrier counts, odds ratio, or confidence interval were reported for p.Ile555Asn. Details ▾Hide ▴
Reasoning

No case-control comparison for NM_004119.2:c.1664T>A (NP_004110.2:p.Ile555Asn) was identified. The reviewed full-text paper reports only gene-level FLT3/FLT3-ITD testing and does not mention this variant, affected-carrier counts, unaffected or population-control carrier counts, an odds ratio, or a confidence interval. Therefore the ACMG/AMP PS4 requirement for significantly increased prevalence in affected individuals compared with controls is not met; no OR or 95% CI can be computed from the available variant-specific data.

Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Note 1: Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • PMID:40637740 paper_extracts entry: the full text does not mention c.1664T>A or p.Ile555Asn and provides no variant-specific case-control counts, OR, or 95% CI; its FLT3 findings are gene-level and include FLT3-ITD testing only.
  • gnomAD v4.1 reports 2/1,614,128 alleles overall and 2/91,076 South Asian alleles, but no affected-case carrier count is available, so a case-control OR and CI cannot be computed from this population frequency alone.
Still missing
  • A variant-specific case-control study with affected and unaffected or matched-ancestry population carrier counts is unavailable.
Sources
PM1 ACMG_2015Not met: FLT3 residue 555 is outside the governing codons 589-599 hotspot, and vcep_materials.json lists no approved critical-domain entry for residue 555. Details ▾Hide ▴
Reasoning

PM1 is not met under the governing rules. The authoritative vcep_materials.json domain_tables key is empty, so it supplies no approved FLT3 critical-domain entry containing residue 555. The governing FLT3 note identifies the classic activating hotspot as codons 589-599 and restricts its PM1 use to in-frame ITD/insertion/duplication/delins events in that hotspot; this variant is a missense SNV at residue 555, outside codons 589-599. No qualifying VCEP-named hotspot or approved critical functional-domain route applies to residue 555, and the case hotspot result is negative.

Rule
Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation.
Evidence considered
  • flt3_itd_hotspot_and_function.md.txt states that the classic juxtamembrane FLT3 ITD hotspot includes codons 589-599 and limits its use to ITD/activating length-mutation events.
  • vcep_materials.json has domain_tables: {}, so there is no authoritative approved FLT3 critical-domain interval to include residue 555.
  • The case evidence reports that this variant does not lie in a statistically significant hotspot.
Sources
vcep_flt3_itd_hotspot_and_functionhotspots ↗
PM5 ACMG_2015Not met: no different pathogenic missense variant at FLT3 residue 555 was identified, and the local PM5 note excludes this missense SNV. Details ▾Hide ▴
Reasoning

PM5 is not met. The generic PM5 rule requires a novel missense change at a residue where a different missense change determined to be pathogenic has been seen before. The case evidence reports zero collected same-residue PM5 candidates, and no alternate pathogenic missense at FLT3 residue 555 was identified. The local FLT3 PM5 guidance is restricted to novel in-frame ITDs or activating length mutations, not this missense SNV, so it cannot supply generic missense PM5 evidence.

Rule
Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before. ... Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level.
Evidence considered
  • The case PM5 candidate summary reports zero total candidates and zero same-residue candidates.
  • flt3_itd_hotspot_and_function.md.txt and flt3_oncokb_guidance.md.txt define local PM5 logic for ITD/activating length-mutation events, not missense substitutions.
Still missing
  • No c.1664T>A, p.Ile555Asn, or p.I555N entry was found in flt3_itd_hotspot_and_function.md.txt.
  • No c.1664T>A, p.Ile555Asn, or p.I555N entry was found in flt3_oncokb_guidance.md.txt.
Sources
vcep_flt3_itd_hotspot_and_functionvcep_flt3_oncokb_guidancepm5_candidates
PP3 ACMG_2015Not met: missense REVEL score 0.561 is below the PP3 supporting threshold of >= 0.644. Details ▾Hide ▴
Reasoning

The variant is a missense SNV, so the generic PP3 missense path is REVEL only; SpliceAI is excluded and BayesDel has no established generic ACMG-strength calibration. REVEL is 0.561, below the supplied PP3 supporting threshold of >= 0.644, so PP3 is not met.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.).
Evidence considered
  • NM_004119.2:c.1664T>A is a missense substitution producing NP_004110.2:p.(Ile555Asn); the governing generic path therefore uses REVEL only.
  • Local REVEL lookup reports 0.561. The supplied ClinGen SVI calibration threshold for PP3 supporting is >= 0.644 (Pejaver et al. 2022, PMID:36413997); 0.561 does not reach it.
  • The available SpliceAI score was not used because the generic rule selects REVEL for missense variants, and BayesDel was not used because no generic ACMG-strength calibration is established.
Sources
revel
PP5 ACMG_2015Not met: the exact variant has no ClinVar expert-panel pathogenic or likely pathogenic classification. Details ▾Hide ▴
Reasoning

The exact variant is absent from the available ClinVar record and no exact-variant ClinVar expert-panel classification as pathogenic or likely pathogenic is present. Ordinary submissions, aggregate labels, and non-expert assertions would not qualify, and none are available here.

Rule
Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar exact-variant lookup for NM_004119.2:c.1664T>A returned absent, with zero submissions and zero expert-panel submissions.
BA1 ACMG_2015Not met: gnomAD v4.1 grpmax FAF is 3.65e-06 (0.000365%), far below the >=0.05 BA1 threshold. Details ▾Hide ▴
Reasoning

BA1 is not met. The governing default threshold is >=0.05, whereas the appropriate gnomAD filtering frequency is the gnomAD v4.1 grpmax FAF of 3.65e-06 (0.000365%), well below 5%. The highest observed South Asian point estimate (2.19597e-05; 2/91,076 alleles) does not replace grpmax FAF, and the population has >2,000 observed alleles. No disease-specific high-frequency exception or pathogenic consensus is present that would require withholding BA1 beyond this frequency result.

Rule
Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v4.1 reports total AF 1.23906e-06 (2/1,614,128 alleles), highest observed South Asian AF 2.19597e-05 (2/91,076 alleles), and grpmax FAF=3.65e-06.
  • For BA1/BS1, the filtering grpmax FAF is used rather than the South Asian popmax point estimate; the South Asian population contains 91,076 observed alleles, exceeding the 2,000-allele minimum specified for this interpretation.
  • The supplied generic BA1 calibration is >=0.05 (ACMG/AMP 2015; PMID:25741868).
Sources
BS1 ACMG_2015Not met: gnomAD v4.1 grpmax FAF is 3.65e-06 (0.000365%), below the generic 0.01 BS1 threshold. Details ▾Hide ▴
Reasoning

BS1 is not met on the available population evidence. The relevant gnomAD v4.1 filtering frequency is grpmax FAF=3.65e-06 (0.000365%), below the supplied generic BS1 default of 0.01 (1%). The highest South Asian point estimate is only 2.19597e-05 and is not used for this decision. There is no elevated ancestry-specific frequency requiring a Whiffin maximum-credible-frequency calculation, and no evidence that prevalence, penetrance, or allelic heterogeneity would make this low frequency greater than expected for the disorder.

Rule
Allele frequency is greater than expected for the disorder.
Evidence considered
  • gnomAD v4.1 reports grpmax FAF=3.65e-06; the highest observed South Asian point estimate is 2.19597e-05 from 2/91,076 alleles.
  • The supplied generic BS1 default is >=0.01 (1%); the filtering grpmax FAF, not the popmax point estimate, is the required frequency figure.
  • No per-gene maximum-credible-frequency calculation is needed because the filtering frequency is far below the generic threshold and is not elevated in an ancestry with a documented reduced-penetrance or founder-allele concern.
Sources
BP4 ACMG_2015Not met: missense REVEL score 0.561 is above the BP4 supporting threshold of <= 0.29. Details ▾Hide ▴
Reasoning

The variant is a missense SNV, so the generic BP4 missense path is REVEL only; SpliceAI is excluded. REVEL is 0.561, above the supplied BP4 supporting threshold of <= 0.29, so BP4 is not met. The SpliceAI result cannot substitute for the indeterminate missense REVEL result.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc).
Evidence considered
  • NM_004119.2:c.1664T>A is a missense substitution producing NP_004110.2:p.(Ile555Asn); the governing generic path therefore uses REVEL only.
  • Local REVEL lookup reports 0.561. The supplied ClinGen SVI calibration threshold for BP4 supporting is <= 0.29 (Pejaver et al. 2022, PMID:36413997); 0.561 does not reach it.
  • SpliceAI max delta 0.037 was not used because splice prediction is not the applicable generic path for a missense variant; an indeterminate REVEL result does not authorize substituting SpliceAI.
Sources
revel
BP6 ACMG_2015Not met: the exact variant has no ClinVar expert-panel benign or likely benign classification. Details ▾Hide ▴
Reasoning

The exact variant is absent from the available ClinVar record and no exact-variant ClinVar expert-panel classification as benign or likely benign is present. Ordinary submissions, aggregate labels, and non-expert assertions would not qualify, and none are available here.

Rule
Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar exact-variant lookup for NM_004119.2:c.1664T>A returned absent, with zero submissions and zero expert-panel submissions.

Not assessed · 12 · no assessment recorded

PS2 ACMG_2015Not assessed: no proband-level de novo evidence or confirmed maternity and paternity testing is available for p.Ile555Asn. Details ▾Hide ▴
Reasoning

No case-level evidence establishes that NM_004119.2:c.1664T>A (p.Ile555Asn) occurred de novo. The available records do not provide a proband phenotype/disease diagnosis, family-history assessment, or confirmed maternity and paternity testing. Therefore the Richards 2015 PS2 requirements cannot be evaluated.

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • The case evidence contains no proband-level pedigree, parental testing, maternity/paternity confirmation, or de novo report for NM_004119.2:c.1664T>A (NP_004110.2:p.(I555N)).
  • PMID:40637740 was reviewed; its extraction states that c.1664T>A/p.I555N is not mentioned and provides no variant-specific clinical or segregation information.
Still missing
  • Documented disease phenotype and absence of family history in the proband
  • Variant testing results for the proband and both biological parents
  • Confirmed maternity and paternity
Sources
PS3 ACMG_2015Not assessed: no variant-specific functional assay was identified, and OncoKB reports Unknown Oncogenic Effect rather than exact-variant functional evidence. Details ▾Hide ▴
Reasoning

NM_004119.2:c.1664T>A (NP_004110.2:p.(Ile555Asn), p.I555N) is a missense substitution. No variant-specific in vitro or in vivo functional assay result was identified in the collected evidence. OncoKB reports Unknown Oncogenic Effect and did not identify variant-specific reviewed functional evidence; therefore the exact-variant functional-support route is unavailable. The FLT3 VCEP files were searched under c.1664T>A, p.Ile555Asn, and p.I555N, but neither file contains a row for this variant. The available PMID:40637740 paper reports only gene-level FLT3-ITD testing and does not mention this variant. Class-level FLT3 ITD activation literature in the local notes cannot establish damaging function for this distinct missense substitution under generic ACMG/AMP 2015. Evidence is insufficient to determine whether PS3 is met.

Rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
Evidence considered
  • OncoKB exact-event review for FLT3 p.I555N reports classification Unknown Oncogenic Effect and states that no variant-specific reviewed functional evidence was identified.
  • The variant is normalized as NM_004119.2:c.1664T>A, NP_004110.2:p.(Ile555Asn), p.I555N, and as a missense substitution; the local FLT3 ITD/activating-length framework is restricted to in-frame insertions, duplications, delins, ITDs, and length mutations, so generic ACMG/AMP rules apply.
  • The local FLT3 notes describe class-level FLT3 ITD activation, but no exact p.I555N functional result; class-level evidence does not establish damaging function for this missense substitution.
  • PMID:40637740 reports FLT3-ITD testing in a prospective AML cohort but does not explicitly mention FLT3 c.1664T>A or NP_004110.2:p.(I555N), and provides no variant-specific functional result.
Still missing
  • No variant-specific in vitro or in vivo functional assay result was identified for NM_004119.2:c.1664T>A (p.Ile555Asn/p.I555N).
  • No matching entry was found in flt3_itd_hotspot_and_function.md.txt when searched for c.1664T>A, p.Ile555Asn, and p.I555N.
  • No matching entry was found in flt3_oncokb_guidance.md.txt when searched for c.1664T>A, p.Ile555Asn, and p.I555N.
  • The available literature record PMID:40637740 does not report variant-specific functional data for p.I555N.
Sources
oncokb ↗PMID:40637740 ↗vcep_flt3_itd_hotspot_and_functionvcep_flt3_oncokb_guidance
PM6 ACMG_2015Not assessed: no assumed de novo occurrence or parental testing data are reported for p.Ile555Asn. Details ▾Hide ▴
Reasoning

No case-level evidence establishes an assumed de novo occurrence of NM_004119.2:c.1664T>A (p.Ile555Asn). The available records do not identify a proband with the disease, a family-history assessment, or parental testing showing absence of the variant; consequently, the PM6 definition cannot be evaluated.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • The case evidence contains no proband-level report, pedigree, or parental genotype data for NM_004119.2:c.1664T>A (NP_004110.2:p.(I555N)).
  • PMID:40637740 was reviewed; its extraction states that c.1664T>A/p.I555N is not mentioned and provides no variant-specific clinical or segregation information.
Still missing
  • Documented disease phenotype and family-history assessment
  • Parental genotype results or a documented basis for assuming de novo status
  • Proband genotype confirmation
Sources
PP1 ACMG_2015Not assessed: zero affected relatives and zero informative co-segregating meioses are documented for p.Ile555Asn. Details ▾Hide ▴
Reasoning

No affected family members, informative meioses, or genotype-phenotype co-segregation observations are reported for NM_004119.2:c.1664T>A (p.Ile555Asn). The available evidence therefore cannot establish PP1 or support a stronger segregation level.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease. ... May be used as stronger evidence with increasing segregation data.
Evidence considered
  • The case evidence contains no pedigree, affected-relative testing, meiosis count, or segregation result for NM_004119.2:c.1664T>A (NP_004110.2:p.(I555N)).
  • PMID:40637740 was reviewed; its extraction states that c.1664T>A/p.I555N is not mentioned and provides no variant-specific clinical or segregation information.
Still missing
  • Pedigree identifying affected relatives
  • Genotypes and phenotypes for informative family members
  • Number of informative meioses and segregation results
Sources
PP2 ACMG_2015Not assessed: the required FLT3 benign-missense rate and evidence that missense variants commonly cause disease are not provided. Details ▾Hide ▴
Reasoning

PP2 is not assessed because the required gene-level inputs are not available under the governing rules. The evidence bundle does not provide a validated FLT3 gene-level rate of benign missense variation or an established disease mechanism showing that missense variants are a common mechanism of disease. Somatic FLT3 mutation recurrence and class-level ITD activation do not establish both generic PP2 conditions for this germline missense interpretation.

Rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
Still missing
  • Validated gene-level evidence for a low rate of benign FLT3 missense variation is unavailable.
  • Validated evidence that FLT3 missense variants are a common disease mechanism is unavailable.
PP4 ACMG_2015Not assessed: no patient phenotype, family history, or disease diagnosis is available to evaluate phenotype specificity. Details ▾Hide ▴
Reasoning

The case materials provide no patient phenotype, family history, or disease diagnosis for this variant. Without clinical phenotype information, specificity for a disease with a single genetic etiology cannot be evaluated.

Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Still missing
  • The patient's clinical phenotype, family history, and confirmed disease diagnosis are needed.
BS2 ACMG_2015Not assessed: gnomAD has 0 homozygotes, but disease model, penetrance, and healthy-adult status for the rare heterozygotes are unavailable. Details ▾Hide ▴
Reasoning

BS2 is not assessed. gnomAD shows no homozygotes (0 in gnomAD v2.1 and 0 in gnomAD v4.1) and only rare heterozygous observations, but the available records do not establish that these are healthy adult individuals unaffected by a specific FLT3 disorder, nor that the relevant disorder is a fully penetrant early-onset recessive, dominant, or X-linked condition. The required disease model, penetrance, and adult health status are therefore unavailable.

Rule
Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Evidence considered
  • gnomAD v2.1 reports 1/251,454 alleles and 0 homozygotes; gnomAD v4.1 reports 2/1,614,128 alleles and 0 homozygotes.
  • The gnomAD population summaries do not provide the individual-level clinical status, age, penetrance, or disease-model information required to establish BS2.
Still missing
  • A defined FLT3 disorder with inheritance, expected penetrance, and age of onset is needed.
  • Individual-level evidence confirming unaffected healthy-adult status is needed for observed carriers.
Sources
BS3 ACMG_2015Not assessed: no variant-specific assay demonstrated a lack of damaging effect on FLT3 protein function or splicing. Details ▾Hide ▴
Reasoning

NM_004119.2:c.1664T>A (NP_004110.2:p.(Ile555Asn), p.I555N) is a missense substitution. No well-established variant-specific in vitro or in vivo functional study demonstrating no damaging effect on protein function or splicing was identified. OncoKB reports Unknown Oncogenic Effect and no variant-specific reviewed functional evidence, which is not evidence of a benign functional effect. PMID:40637740 does not mention this variant or provide a benign functional assay result. The FLT3 VCEP files were searched under c.1664T>A, p.Ile555Asn, and p.I555N, with no matching row in either file. Evidence is insufficient to determine whether BS3 is met.

Rule
Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • OncoKB exact-event review reports Unknown Oncogenic Effect and no variant-specific reviewed functional evidence; this does not demonstrate a lack of damaging effect.
  • PMID:40637740 reports gene-level FLT3-ITD testing but does not explicitly mention FLT3 c.1664T>A or NP_004110.2:p.(I555N), and provides no benign functional assay result.
  • Neither searched FLT3 VCEP reference file contains an exact-variant row for c.1664T>A, p.Ile555Asn, or p.I555N.
Still missing
  • No variant-specific well-established in vitro or in vivo study demonstrating no damaging effect on protein function or splicing was identified for NM_004119.2:c.1664T>A (p.Ile555Asn/p.I555N).
  • No matching entry was found in flt3_itd_hotspot_and_function.md.txt when searched for c.1664T>A, p.Ile555Asn, and p.I555N.
  • No matching entry was found in flt3_oncokb_guidance.md.txt when searched for c.1664T>A, p.Ile555Asn, and p.I555N.
  • The available literature record PMID:40637740 does not report variant-specific benign functional data for p.I555N.
Sources
oncokb ↗PMID:40637740 ↗vcep_flt3_itd_hotspot_and_functionvcep_flt3_oncokb_guidance
BS4 ACMG_2015Not assessed: no affected relatives have documented negative testing, so no non-segregation event is available for BS4. Details ▾Hide ▴
Reasoning

No affected family members have been identified and tested for NM_004119.2:c.1664T>A (p.Ile555Asn), so there is no documented non-segregation observation. BS4 cannot be assessed; the caveat concerning phenocopies and families with more than one pathogenic variant cannot be evaluated without a pedigree and family genotypes.

Rule
Lack of segregation in affected members of a family.
Evidence considered
  • The case evidence contains no affected-relative testing, pedigree, or documented non-segregation result for NM_004119.2:c.1664T>A (NP_004110.2:p.(I555N)).
  • PMID:40637740 was reviewed; its extraction states that c.1664T>A/p.I555N is not mentioned and provides no variant-specific clinical or segregation information.
Still missing
  • Pedigree with affected relatives
  • Genotype results for affected relatives
  • Clinical assessment sufficient to evaluate phenocopies or multiple pathogenic variants
Sources
BP1 ACMG_2015Not assessed: no validated evidence shows that FLT3 disease is caused primarily by truncating variants. Details ▾Hide ▴
Reasoning

BP1 is not assessed because the required gene-level disease-spectrum evidence is not available under the governing rules. The case evidence does not establish that FLT3 disease is caused primarily by truncating variants, and the available FLT3 material concerns somatic ITD/activating biology rather than a validated germline variant-spectrum comparison.

Rule
Missense variant in a gene for which primarily truncating variants are known to cause disease.
Still missing
  • Validated FLT3 disease-spectrum evidence comparing truncating and missense pathogenic mechanisms is unavailable.
BP2 ACMG_2015Not assessed: no reported pathogenic partner variant or parental phase result establishes cis or trans occurrence for p.Ile555Asn. Details ▾Hide ▴
Reasoning

The case materials do not report an affected-proband observation with a pathogenic variant, parental or family testing, or any result establishing that NM_004119.2:c.1664T>A (p.Ile555Asn) is in trans or in cis with a pathogenic variant. Therefore BP2 cannot be assessed from the available allelic evidence.

Rule
BP2: Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • No affected-proband, family, parental-testing, pathogenic-partner, cis-phase, or trans-phase observation is reported in the case materials.
Still missing
  • Determine whether a pathogenic variant is present in the same individual and establish cis/trans phase by parental or other validated phasing data.
BP5 ACMG_2015Not assessed: no case-level alternate molecular basis for disease is documented alongside this variant. Details ▾Hide ▴
Reasoning

The available case materials do not document that this variant was found in a case with an alternate molecular basis for disease. No alternate molecular diagnosis or case-level molecular finding is supplied for evaluation.

Rule
Variant found in a case with an alternate molecular basis for disease.
Still missing
  • A documented alternate molecular diagnosis in the same case is required.
Not applicable · 5· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: c.1664T>A is a missense substitution, not one of the null-variant classes required for PVS1. Details ▾Hide ▴
Reasoning

PVS1 is not applicable because NM_004119.2:c.1664T>A produces the missense substitution NP_004110.2:p.(Ile555Asn) (p.I555N), not a nonsense, frameshift, canonical +/-1 or 2 splice-site, initiation-codon, or exon-deletion variant. The assessed transcript and consequence are explicitly recorded as NM_004119.2 and missense in the variant-level PVS1 assessment; therefore no NMD, exon-importance, or downgrade analysis can activate PVS1 for this substitution.

Rule
PVS1: Null variant (nonsense, frameshift, canonical +/−1 or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of disease.
Evidence considered
  • Variant-level PVS1 assessment: NM_004119.2:c.1664T>A is classified as consequence_class=missense, with protein consequence NP_004110.2:p.(Ile555Asn) / p.(I555N), and apply_generic_pvs1_framework=false.
  • The governing FLT3 note was searched for c.1664T>A, p.Ile555Asn, and p.I555N; no matching row or notation was found.
Still missing
  • No entry for c.1664T>A, p.Ile555Asn, or p.I555N was found in /Users/gs_agent/LYFESCI_HERMES_v12/vcep_db/FLT3/fulltext/flt3_itd_hotspot_and_function.md.txt.
Sources
pvs1_variant_assessment
PM3 N/ANot applicable: PM3 is restricted to recessive disorders, but no recessive FLT3 disorder or in-trans pathogenic allele is established. Details ▾Hide ▴
Reasoning

PM3 is not applicable because its governing definition is limited to recessive disorders, and the case materials provide no recessive FLT3 disorder context. No affected-proband observation, pathogenic allele, parental testing, or phase result establishes a recessive in-trans configuration for NM_004119.2:c.1664T>A (p.Ile555Asn).

Rule
PM3: For recessive disorders, detected in trans with a pathogenic variant
Evidence considered
  • The case materials identify NM_004119.2:c.1664T>A as a missense substitution, p.Ile555Asn, and contain no recessive FLT3 disorder context.
  • No affected-proband, parental-testing, pathogenic-allele, or cis/trans phase observation is reported for this variant.
PM4 N/ANot applicable: p.Ile555Asn changes one amino acid but causes no protein-length change required for PM4. Details ▾Hide ▴
Reasoning

PM4 is not applicable because the variant is a missense substitution that changes Ile555 to Asn without an in-frame insertion, in-frame deletion, or stop-loss event and therefore does not change protein length. The local FLT3 note was searched as required but its PM4 guidance is restricted to in-frame ITD/activating length-mutation events, not this missense SNV; the case framework also releases PM4 to generic rules for this variant type.

Rule
PM4: Protein length changes due to in-frame deletions/insertions in a non-repeat region or stop-loss variants.
Evidence considered
  • Variant-level assessment identifies NM_004119.2:c.1664T>A as a missense substitution producing NP_004110.2:p.(Ile555Asn), so the protein length is unchanged.
  • The on-record FLT3 note states that its PM4 guidance is for canonical juxtamembrane ITD/activating length-mutation events; no exact variant notation was found in the searched file.
Still missing
  • No entry for c.1664T>A, p.Ile555Asn, or p.I555N was found in /Users/gs_agent/LYFESCI_HERMES_v12/vcep_db/FLT3/fulltext/flt3_itd_hotspot_and_function.md.txt.
Sources
pvs1_variant_assessmentvcep_flt3_itd_hotspot_and_function
BP3 N/ANot applicable: p.Ile555Asn is a missense SNV, not an in-frame deletion or insertion in a repetitive region. Details ▾Hide ▴
Reasoning

BP3 is not applicable because the variant is a missense substitution, not an in-frame deletion or insertion in a repetitive region. No repeat-region protein-length event is present, and the local FLT3 note's BP3 guidance is limited to FLT3 in-frame ITDs or activating length mutations in the juxtamembrane hotspot, which excludes this missense SNV; the case framework releases BP3 to generic rules for this variant type.

Rule
BP3: In frame-deletions/insertions in a repetitive region without a known function.
Evidence considered
  • Variant-level assessment identifies NM_004119.2:c.1664T>A as a missense substitution producing NP_004110.2:p.(Ile555Asn), with no in-frame insertion/deletion or protein-length change.
  • The on-record FLT3 note was searched for all three variant notations and contains no matching entry; its BP3 guidance concerns in-frame ITD/activating length mutations rather than missense substitutions.
Still missing
  • No entry for c.1664T>A, p.Ile555Asn, or p.I555N was found in /Users/gs_agent/LYFESCI_HERMES_v12/vcep_db/FLT3/fulltext/flt3_itd_hotspot_and_function.md.txt.
Sources
pvs1_variant_assessmentvcep_flt3_itd_hotspot_and_function
BP7 N/ANot applicable: c.1664T>A is missense with p.(Ile555Asn), not a synonymous variant. Details ▾Hide ▴
Reasoning

BP7 applies only to synonymous variants. NM_004119.2:c.1664T>A is a missense substitution causing p.(Ile555Asn), so the variant is outside BP7 scope and BP7 is not applicable.

Rule
A synonymous variant for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved.
Evidence considered
  • The normalized consequence is missense, NM_004119.2:c.1664T>A -> NP_004110.2:p.(Ile555Asn).

Identifiers

Gene
FLT3
Transcript
NM_004119.2
Coding (HGVS c.)
NM_004119.2:c.1664T>A
Protein (HGVS p.)
NP_004110.2:p.(Ile555Asn)
GRCh38
chr13:28034341 A>T
GRCh37
chr13:28608478 A>T
Location and type
Exon 13 · missense
COSMIC
COSV106090853

Gene diagram

Every interpreted variant in FLT3, mapped onto the exon structure of NM_004119.2. Select a row to find it on the plot.

FLT3NM_004119.2
Fetching transcript structure from UCSC…
gnomAD v4.1 2 / 1,614,128 alleles AF 1.24e-06 · 0 homozygotes · FAF 3.65e-06
gnomAD v2.1 1 / 251,454 alleles AF 3.98e-06 · 0 homozygotes
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 1.2e-06 · 2 / 1,614,128 alleles · 0 hom · FAF 3.7e-06
South Asian2 / 91,076 2.2e-05
0 alternate alleles recorded in 9 other groups: Remaining individuals, Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, Ashkenazi Jewish, African/African American, European (non-Finnish).

gnomAD v2.1

AF 4e-06 · 1 / 251,454 alleles · 0 hom
South Asian1 / 30,616 3.3e-05
0 alternate alleles recorded in 7 other groups: African/African American, Admixed American, Ashkenazi Jewish, East Asian, European (Finnish), European (non-Finnish), Remaining individuals.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 1.23906e-06; MAF= 0.00012%, 2/1614128 alleles, homozygotes = 0) and has highest observed frequency in the South Asian population (AF= 2.19597e-05; MAF= 0.00220%, 2/91076 alleles, homozygotes = 0); grpmax FAF= 3.65e-06.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.97687e-06; MAF= 0.00040%, 1/251454 alleles, homozygotes = 0) and has highest observed frequency in the South Asian population (AF= 3.26627e-05; MAF= 0.00327%, 1/30616 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat -86 bp
0.037
SpliceAI acceptor gainat -135 bp
0.009
SpliceAI donor lossat -134 bp
0.003
SpliceAI donor gainat -52 bp
0.024
Pangolin splice lossmagnitude shown
-0.028
Pangolin splice gain
0.036

Other predictors

REVEL
0.561
BayesDel
-0.014

How the predictions were used

PP3 ACMG_2015Not met: missense REVEL score 0.561 is below the PP3 supporting threshold of >= 0.644. Details ▾Hide ▴
Reasoning

The variant is a missense SNV, so the generic PP3 missense path is REVEL only; SpliceAI is excluded and BayesDel has no established generic ACMG-strength calibration. REVEL is 0.561, below the supplied PP3 supporting threshold of >= 0.644, so PP3 is not met.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.).
Evidence considered
  • NM_004119.2:c.1664T>A is a missense substitution producing NP_004110.2:p.(Ile555Asn); the governing generic path therefore uses REVEL only.
  • Local REVEL lookup reports 0.561. The supplied ClinGen SVI calibration threshold for PP3 supporting is >= 0.644 (Pejaver et al. 2022, PMID:36413997); 0.561 does not reach it.
  • The available SpliceAI score was not used because the generic rule selects REVEL for missense variants, and BayesDel was not used because no generic ACMG-strength calibration is established.
Sources
revel
BP4 ACMG_2015Not met: missense REVEL score 0.561 is above the BP4 supporting threshold of <= 0.29. Details ▾Hide ▴
Reasoning

The variant is a missense SNV, so the generic BP4 missense path is REVEL only; SpliceAI is excluded. REVEL is 0.561, above the supplied BP4 supporting threshold of <= 0.29, so BP4 is not met. The SpliceAI result cannot substitute for the indeterminate missense REVEL result.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc).
Evidence considered
  • NM_004119.2:c.1664T>A is a missense substitution producing NP_004110.2:p.(Ile555Asn); the governing generic path therefore uses REVEL only.
  • Local REVEL lookup reports 0.561. The supplied ClinGen SVI calibration threshold for BP4 supporting is <= 0.29 (Pejaver et al. 2022, PMID:36413997); 0.561 does not reach it.
  • SpliceAI max delta 0.037 was not used because splice prediction is not the applicable generic path for a missense variant; an indeterminate REVEL result does not authorize substituting SpliceAI.
Sources
revel
BP7 N/ANot applicable: c.1664T>A is missense with p.(Ile555Asn), not a synonymous variant. Details ▾Hide ▴
Reasoning

BP7 applies only to synonymous variants. NM_004119.2:c.1664T>A is a missense substitution causing p.(Ile555Asn), so the variant is outside BP7 scope and BP7 is not applicable.

Rule
A synonymous variant for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved.
Evidence considered
  • The normalized consequence is missense, NM_004119.2:c.1664T>A -> NP_004110.2:p.(Ile555Asn).

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.04). REVEL score = 0.561. BayesDel score = -0.0138191.

0 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata.

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 1.23906e-06; MAF= 0.00012%, 2/1614128 alleles, homozygotes = 0) and has highest observed frequency in the South Asian population (AF= 2.19597e-05; MAF= 0.00220%, 2/91076 alleles, homozygotes = 0); grpmax FAF= 3.65e-06.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.97687e-06; MAF= 0.00040%, 1/251454 alleles, homozygotes = 0) and has highest observed frequency in the South Asian population (AF= 3.26627e-05; MAF= 0.00327%, 1/30616 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant is absent from ClinVar.

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.04). REVEL score = 0.561. BayesDel score = -0.0138191.

Functional

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. FLT3, a receptor tyrosine kinase, is recurrently altered in acute myeloid leukemia and other hematologic malignancies.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV106090853, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.